These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32490276)

  • 1. The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges.
    Behzadifar M; Azari S; Gorji HA; Martini M; Bragazzi NL
    J Prev Med Hyg; 2020 Mar; 61(1):E109-E118. PubMed ID: 32490276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-related policy-making in Iran: a stakeholder and social network analysis.
    Behzadifar M; Gorji HA; Rezapour A; Rezvanian A; Bragazzi NL; Vatankhah S
    Health Res Policy Syst; 2019 Apr; 17(1):42. PubMed ID: 30992014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon's multiple streams framework.
    Behzadifar M; Gorji HA; Rezapour A; Bragazzi NL
    Health Res Policy Syst; 2019 Mar; 17(1):30. PubMed ID: 30917837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
    Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
    Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis and evolution of health policies in Iran through policy triangle framework during the last thirty years: a systematic review of the historical period from 1994 to 2021.
    Doshmangir L; Behzadifar M; Shahverdi A; Martini M; Ehsanzadeh SJ; Azari S; Bakhtiari A; Shahabi S; Bragazzi NL; Behzadifar M
    J Prev Med Hyg; 2023 Mar; 64(1):E107-E117. PubMed ID: 37293450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
    Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.
    Lazarus JV; Safreed-Harmon K; Thursz MR; Dillon JF; El-Sayed MH; Elsharkawy AM; Hatzakis A; Jadoul M; Prestileo T; Razavi H; Rockstroh JK; Wiktor SZ; Colombo M
    Semin Liver Dis; 2018 Aug; 38(3):181-192. PubMed ID: 29986353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    Chikovani I; Ompad DC; Uchaneishvili M; Sulaberidze L; Sikharulidze K; Hagan H; Van Devanter NL
    PLoS One; 2019; 14(4):e0216123. PubMed ID: 31034530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to set the agenda for hepatitis C: a theory-driven policy analysis.
    Kind J; Maeschli B; Bruggmann P
    Health Res Policy Syst; 2022 Feb; 20(1):20. PubMed ID: 35164777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenges of hepatitis C management in Iran: A qualitative study with patients.
    Behzadifar M; Azari S; Gorji HA; Rezapour A; Bragazzi NL
    Int J Health Plann Manage; 2020 Jan; 35(1):e56-e65. PubMed ID: 31679166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of hepatitis C virus among street children in Iran.
    Behzadifar M; Gorji HA; Rezapour A; Bragazzi NL
    Infect Dis Poverty; 2018 Oct; 7(1):88. PubMed ID: 30269685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financing of physical rehabilitation services in Iran: a stakeholder and social network analysis.
    Shahabi S; Ahmadi Teymourlouy A; Shabaninejad H; Kamali M; Lankarani KB
    BMC Health Serv Res; 2020 Jul; 20(1):599. PubMed ID: 32611339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining health insurance funds in a fragmented context: what kind of challenges should be considered?
    Bazyar M; Rashidian A; Alipouri Sakha M; Vaez Mahdavi MR; Doshmangir L
    BMC Health Serv Res; 2020 Jan; 20(1):26. PubMed ID: 31915003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis.
    Olyaaeemanesh A; Jaafaripooyan E; Abdollahiasl A; Davari M; Mousavi SM; Delpasand M
    Health Res Policy Syst; 2021 Dec; 19(1):150. PubMed ID: 34949207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.
    Hasan F; Alfadhli A; Al-Gharabally A; Alkhaldi M; Colombo M; Lazarus JV
    World J Gastroenterol; 2020 Aug; 26(30):4415-4427. PubMed ID: 32874054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Virus Carriers' and HIV testing: navigating Ukraine's HIV policies and programming for female sex workers.
    Tokar A; Osborne J; Slobodianiuk K; Essink D; Lazarus JV; Broerse JEW
    Health Res Policy Syst; 2019 Feb; 17(1):23. PubMed ID: 30819203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.